Asia Pacific

Ilfryn Carstairs, global chief investment officer at alternative investor Värde Partners, will become co-CEO from next year, while keeping his co-CIO title.

China’s National Development and Reform Commission (NDRC) has tightened regulations on property companies selling bonds in the overseas market. Those with free market instincts ─ including this paper ─ would typically balk at such heavy-handedness. But a tough stance is exactly what the market needs to become sustainable in the long-run.

HSBC China has appointed Zuocheng Ding as head of loan origination, according to a source close to the situation.

Europe’s equity capital markets professionals are looking ahead to the next crop of IPOs in September but investors are insisting to sellers that they are a picky bunch when it comes to what they will buy and at what price.

BMW returned to China’s auto loan ABS market on Tuesday with a Rmb8bn ($1.2bn) two-tranche deal, its largest issuance so far, and received a big thumbs-up from investors.

Cifi Holdings (Group) Co, a Chinese real estate developer, made its second venture into the offshore renminbi bond market on Tuesday, taking Rmb1.6bn ($233m) from a tightly priced issuance.

Hong Kong’s Citychamp Watch & Jewellery Group has closed a $150m term loan with five lenders.

A busy day for bond issuance from Chinese property companies offered investors a dash of variety, as investment grade rated China Jinmao Holdings Group vied for attention amid a slew of deals from high yield credits including Kaisa Group Holdings.

India’s Adani Ports and Special Economic Zone has bagged $650m from 144A/Reg S bonds to fund a tender offer of notes due next year, pricing the new issuance at a competitive level.

Crédit Agricole has nabbed one of HSBC’s former sustainability bond leads to work on its sustainable financing team in Asia.

Investors in London have been considering the opportunity to invest in Uzbekistan this week, through a new closed-end fund, Oltin, the first internationally listed security giving investors exposure to the Central Asian republic.

Chinese biopharmaceutical company Alphamab Oncology is planning to start sounding out investors for its Hong Kong IPO later this week, according to a source close to the transaction.